Search Results

You are looking at 61 - 70 of 108 items for :

  • "Bladder cancer" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

James Perkins, Patrick Boland, Steven J. Cohen, Anthony J. Olszanski, Yan Zhou, Paul Engstrom, and Igor Astsaturov

bladder cancer has been documented, but this strategy is not considered to be a standard treatment option. 13 The mechanism through which KIF11 inhibition produced such a dramatic response in the present patient, whose tumor was refractory to chemotherapy

Full access

Kelsey C. Stoltzfus, Biyi Shen, Leila Tchelebi, Daniel M. Trifiletti, Niraj J. Gusani, Vonn Walter, Ming Wang, and Nicholas G. Zaorsky

addition, a study of patients with muscle-invasive bladder cancer found no difference in survival between patients treated at a high-volume versus low-volume facility (HR, 0.99; 95% CI, 0.94–1.04). 9 Mixed findings across different cancer sites may be

Full access

Jarushka Naidoo

cisplatin-ineligible bladder cancer, patients may receive atezolizumab or pembrolizumab, using 2 different PD-L1 biomarkers. Atezolizumab uses the SP142 antibody with a PD-L1 IHC cutoff of 5% for immune cells only. Pembrolizumab uses a different scoring

Full access

Muhammed Aasim Yusuf, Vinay Kumar Kapoor, Refaat Refaat Kamel, Ather Kazmi, Najam Uddin, Nehal Masood, and Abdulmajeed Al-Abdulkareem

). Regarding gall bladder cancer, the highest incidence rates worldwide were reported for women in Delhi, India (21.5/100,000); South Karachi, Pakistan (13.8/100,000); and Quito, Ecuador (12.9/100,000). 6 Risk factors for gallbladder cancer include gallstones

Full access

across different racial subgroups are warranted. CLO20-055: Optimal Timing of Radical Surgery From Diagnosis in Muscle Invasive Bladder Cancer (MIBC) Saurabh Parasramka, MD; Quan Chen, DrPH; Bin Huang, DrPH., MS; Peng Wang, MD, PhD; and Zin Myint, MD

Full access

Myeloid Leukemia Bladder Cancer Breast Cancer Genetic/Familial High-Risk Assessment: Breast and Ovarian Genetic/Familial High-Risk Assessment: Colorectal Hodgkin Lymphoma Lung Cancer Screening Neuroendocrine Tumors Pancreatic Adenocarcinoma

Full access

these agents into routine care.” Several checkpoint inhibitors have already been FDA-approved for various cancers, including melanoma, Hodgkin lymphoma, and lung, liver, kidney, and bladder cancers. The use of checkpoint inhibitors is continuously

Full access

V.1.2014; Acute Myeloid Leukemia V.2.2014; Bladder Cancer V.2.2014; Chronic Myelogenous Leukemia V.3.2014; Hodgkin Lymphoma (V.2.2013); Multiple Myeloma (V.2.2014); Myeloid Growth Factors (V.2.2013); Systemic Light Chain Amyloidosis (V.2

Full access

Nikolai A. Podoltsev, Mengxin Zhu, Amer M. Zeidan, Rong Wang, Xiaoyi Wang, Amy J. Davidoff, Scott F. Huntington, Smith Giri, Steven D. Gore, and Xiaomei Ma

: https://healthcaredelivery.cancer.gov/seermedicare/considerations/date.html . Accessed September 14, 2018. 18. Hollenbeck BK , Ye Z , Dunn RL , . Provider treatment intensity and outcomes for patients with early-stage bladder cancer . J Natl

Full access

Harish N. Vasudevan and Sue S. Yom

RT has demonstrated improved outcomes in lung cancer, 1 gastrointestinal malignancies, 2 – 4 glioblastoma, 5 bladder cancer, 6 and HNC. 7 , 8 Broadly, numerous mechanisms underlie the interactions observed between these 2 treatment modalities